Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) shares shot up 12.5% during trading on Tuesday . The stock traded as high as $1.1245 and last traded at $1.1245. 213 shares were traded during mid-day trading, a decline of 92% from the average session volume of 2,663 shares. The stock had previously closed at $1.00.
Vaccinex Stock Performance
The company has a 50 day simple moving average of $0.75 and a 200 day simple moving average of $0.71. The company has a market capitalization of $2.92 million, a PE ratio of -0.02 and a beta of 1.10.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Further Reading
- Five stocks we like better than Vaccinex
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
